DeLucia David 4

What Happened

• David DeLucia, Chief Financial Officer of Kyntra Bio, was granted a derivative equity award for 26,000 shares on February 3, 2026. The reported acquisition price is $0.00, so no cash was paid for the award at grant. This is a compensation award (transaction code A), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-03; Form 4 filed: 2026-02-05 (timely).
• Security: derivative equity award for 26,000 shares; reported price: $0.00; total reported value at grant: $0.
• Vesting: vests in equal amounts quarterly over four years measured from 2/3/2026 (footnote).
• Shares owned after transaction: not specified in the provided filing.
• No 10b5-1 plan, tax withholding, or sale reported in this filing.

Context

• This is a typical time-based compensation award that vests over several years and is intended to retain executives; it does not represent an immediate purchase or sale of shares. Because the award vests over time, the economic benefit is realized gradually as vesting occurs (and tax/eventual exercise or delivery rules apply).